Impact of ICER Reports on Hemophilia Treatment Decisions

EP: 1.Management Insights for Patients With Hemophilia

EP: 2.Coverage Decisions for Expensive Hemophilia Treatments

Now Viewing

EP: 3.Impact of ICER Reports on Hemophilia Treatment Decisions

EP: 4.Enhancing Provider Access and Expertise for Rare Disease Care

EP: 5.Factors Impacting Hemophilia A Care Costs

EP: 6.Collaborative Strategies in Hemophilia A Care Cost Management

EP: 7.Strategies to Manage Medication Costs and Waste

EP: 8.Adapting to Novel Hemophilia A Treatments

EP: 9.Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP: 10.Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

EP: 11.Hemophilia A Treatment Factors and Outcomes

EP: 12.Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP: 13.Consequences of Nonadherence in Hemophilia A

EP: 14.Advancements in Hemophilia A Therapies

EP: 15.Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP: 16.Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP: 17.Emicizumab Dosing: Prophylaxis and Bleeding Management

EP: 18.Optimizing Hemophilia Treatment: Strategies and Adherence

EP: 19.Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP: 20.Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

Russell P. Gollard, MD, FACP: I think that in terms of our concern with doing not just what is best for the patient but as adherence to the philosophical construct known as population health, we want to do the most effective treatment for the least cost. If we have the availability of newer agents or modalities of care that can reduce the total cost of care during the lifetime of the patient, or of the horse, we’re very, very interested in that. I think the value of emicizumab is really great, given that this drug does not have many of the adverse effects of some of the other agents we use and, in fact, reduces the number of bleeds, particularly the number of major bleeds which we see in patients. The fact that we’re able to use an engineered monoclonal antibody to interfere with the lack of factor 8 and the proclivity toward developing major bleeds has a great economic impact on the cost of care. Also, in the end, has a very beneficial effect on the overall health of the patient.

Transcript is AI generated and reviewed by an AJMC editor.